Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer
Sponsor: AstraZeneca
This PHASE1 trial investigates Metastatic Anaplastic Thyroid Cancer and is currently completed. AstraZeneca leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2019 — May 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .